Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. FDA Globalization Efforts Gain Traction Even As Budget Request Emphasizes Old Inspection Model

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA would gain a boost in funding for overseas manufacturing facility inspections in President Obama's fiscal year 2012 budget, even though the agency has acknowledged its model is unsustainable and is planning changes

You may also be interested in...



Global GMPs: How Much Faith Will U.S. FDA Put In Private Third-Party Audits?

Private and third-party audits may not replace U.S. FDA's typical inspection duties, but could help direct the agency to problematic facilities and relieve some of the inspection burden on those that already are compliant

Global GMPs: How Much Faith Will U.S. FDA Put In Private Third-Party Audits?

Private and third-party audits may not replace U.S. FDA's typical inspection duties, but could help direct the agency to problematic facilities and relieve some of the inspection burden on those that already are compliant

FDA's Competing Budget Aims: Frugality Versus Launching New Initiatives

FDA's proposed fiscal year 2012 budget provides a modest 7% increase in federal appropriations for the human drugs program, which also will benefit from a hefty 46% increase in PDUFA user fees.

Related Content

Latest News
UsernamePublicRestriction

Register

SC077568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel